TGFβR-KO CAR-EGFR T Cell Therapy (Chinese PLA General Hospital)

N/A

Report date: 2022/12/03 20:00:24

Base Information

Drug NameTGFβR-KO CAR-EGFR T Cell Therapy (Chinese PLA General Hospital)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionTransforming growth factor beta inhibitors
TargetsTransforming growth factor beta
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPla General Hospital
China Registration ClassN/A

Develop Information

Active CompaniesPla General Hospital
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A